S&P: Alpharma unaffected

Standard & Poor's said Monday that the announcement that Alpharma Inc. (B/negative/--) is launching the drug gabapentin does not affect the ratings and outlook on the company.

Gabapentin is the generic version of Pfizer Inc.'s antiseizure medication Neurontin. While Alpharma holds the 180-day exclusivity on the capsule version of gabapentin, and the drug represents a significant revenue and deleveraging opportunity for Alpharma, its ultimate revenue potential to Alpharma is uncertain, given that it has to compete with Ivax Corp.'s tablet version of gabapentin, already on the market, S&P said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.